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Recognition Elements on Binding and Transcription Activation*
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Pax-3, a transcription factor that is required for de-
velopment of the embryonic neural tube, neural crest,
and somitic derivatives, contains two DNA-binding do-
mains, a paired domain, and a paired-type homeodo-
main. Although Pax-3 binds to sequences related to the
e5 element of the Drosophila even-skipped gene, the se-
quence requirements of an optimal Pax-3 response ele-
ment have not been well characterized. Using both DNA-
binding domains and a pool of random oligonucleotides,
we identified a new paired box consensus motif, “GT-
TAT,” which was located 1, 4, 5, 8, or 13 base pairs down-
stream of the homeobox binding motif, “ATTA.” Binding
analysis of these sequences demonstrated that the dis-
tance between recognition elements for the homeodo-
main and the paired domain affects affinity. Specifi-
cally, spacing elements 1 or 13 base pairs apart from
each other conferred low affinity Pax-3 binding,
whereas intermediate spacing (5 or 8 base pairs) con-
ferred high affinity binding. Contrary to previous re-
ports, oligonucleotides deleted for either the ATTA or
the GTTAT could also be bound by Pax-3, although both
sites were necessary for maximal affinity. Finally, tran-
sient transfections demonstrated that Pax-3 trans-acti-
vation correlated with binding affinity. Because the
Pax-3-responsive genes identified to date contain almost
exclusively low affinity binding sequences, our analysis
indicates that they may be responsive to Pax-3 only
when cellular levels are high.
Pax-3 encodes a bipartite DNA-binding transcription factor
that is essential for vertebrate embryogenesis. The two DNA-
binding domains consist of a 128-amino acid paired domain,
which itself is comprised of two helix-turn-helix subdomains
that bind to distinct DNA recognition sequences (1, 2), and a
61-amino acid paired-type homeodomain. In the mouse embryo,
expression of Pax-3 begins on day 8.5 in the dorsal neuroepi-
thelium along the anterior-posterior axis (3). By day 9.5, Pax-3
expression extends into the lateral dermomyotome, somitic
mesoderm, and neural crest (3). The Pax-3 gene is essential for
differentiation of the neural tube and other Pax-3-expressing
tissues, as mutation or deletion of the gene is responsible for
the Splotch phenotype in mice (4–6), which is associated with
exencephaly and/or spina bifida with 100% penetrance in ho-
mozygous embryos (7). Similarly, reduced expression of Pax-3
in embryos of diabetic mice causes exencephaly (8), indicating
that a threshold level of functional protein is critical for proper
neural tube development. The amino acid sequence of the mu-
rine Pax-3 paired domain is 100% identical to the human
PAX-3 paired domain, suggesting that it performs similar reg-
ulatory functions during embryogenesis of mice and humans
(9). Indeed, mutations in the human PAX-3 gene have been
found in patients with Waardenburg Syndrome (9–11), an au-
tosomal dominant phenotype characterized by neural crest de-
fects, including pigmentation disturbances, lateral displace-
ment of the inner canthus of the eye, and occasional deafness
and mental retardation. Additional evidence of Pax-3’s role in
regulatory processes is that in humans, the pediatric solid
tumor, alveolar rhabdomyosarcoma, appears to result from a
genetic translocation which causes production of a fusion pro-
tein comprised of the DNA-binding domains of PAX-3 and the
trans-activation domain of the FKHR protein (12–14).
The prototypical paired domain was first identified in the
protein products of several Drosophila segmentation genes,
including paired (prd) and gooseberry (gsb) (15–17). The Dro-
sophila Prd protein binds specifically to the e5 sequence found
in the promoter of the Drosophila even-skipped gene (18, 19).
Like the Drosophila Prd protein, murine Pax-3 can bind spe-
cifically to the e5 sequence (3). Nuclease protection analysis
has suggested that the Pax-3 homeodomain binds to an ATTA
motif within the e5 sequence, and the paired domain binds to a
GTTCC core motif (20), which is 5 bp1 downstream of the
ATTA. Study of the effects of base substitution within the
paired domain binding element of e5 have indicated that Pax-3
binding can tolerate some sequence variation at the last three
positions within the 5-bp core paired recognition element (9,
17). Although each of the DNA-binding domains of Drosophila
Prd can bind to e5 recognition elements independent of the
other (18, 21), albeit with lower affinity than binding by both
domains together (2), previous studies have demonstrated that
Pax-3 binding to e5 oligonucleotides requires both the home-
odomain binding sequence and the paired domain binding se-
quence (20). Furthermore, localization of the paired domain
and homeodomain recognition elements within 2–10 bp of each
other has been found to be essential for Pax-3 binding (22).
These results would indicate that a sequence, ATTA-N2–10-
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GTT/CAT/C is important for Pax-3 binding and transcription
regulation. However, among the few genes that are positively
or negatively regulated by Pax-3 in vertebrate embryos, includ-
ing myelin basic protein, N-CAM, c-Met, and myoD (23–27),
only the chicken myoD promoter contains an element with both
the homeodomain and paired domain recognition sequences
within the vicinity of one another that is thought to be required
for binding. In the case of the N-CAM promoter, a Pax-3 vari-
ant containing just the paired domain is able to bind to a
Pax-3-responsive region, but the intact protein is not (24). This
suggests that additional analysis of the sequence determinants
for Pax-3 binding must be performed to identify putative Pax-3
response elements in its downstream regulated genes.
We report here the identification of a new consensus se-
quence for Pax-3 binding from a pool of random oligonucleo-
tides using both the DNA-binding domains of Pax-3. Oligonu-
cleotides containing variations of the consensus sequence were
evaluated for Pax-3 binding affinity and for trans-activation by
Pax-3. From these results, a model in which the magnitude of
transcriptional responsiveness of target genes depends on
binding affinity is presented.
EXPERIMENTAL PROCEDURES
GST/Pax-3 Fusion Protein Construction with the Pax-3 DNA-bind-
ing Domains—The RF1-Pax-3 expression plasmid (28), kindly provided
by George Chalepakis (Max-Planck Institute for Biophysical Chemis-
try, Germany), was used as a template for PCR amplification of a
775-bp region surrounding the complete paired box and paired-type
homeobox of the Pax-3 cDNA using the forward and reverse primers,
ACTGCGAATTCGCTGGAAGTG and TGACGGAATTCATCAGTT-
GATTGGC, respectively. Each primer was designed to contain an
EcoRI restriction site at the 59 terminus of the PCR product. PCR
reactions contained 0.2 mM each of the above Pax-3 primers, 180 ng
RF1/Pax-3 DNA, 0.5 mM dNTP, 1 3 PCR buffer, and 1 unit of AmpliTaq
(Perkin-Elmer). 30 cycles were performed using the following condi-
tions: 95 °C for 2 min, 50 °C for 1 min, 72 °C for 1 min, followed by a 5
min extension at 72 °C. The entire PCR reaction was digested with
EcoRI and electrophoresed on a 1.2% agarose gel, from which the
795-bp fragment was isolated using the Geneclean kit (Bio-101, Inc.)
using the manufacturer’s suggestions. This fragment was ligated into
EcoRI-digested, dephosphorylated pGEX-3X plasmid (Amersham Phar-
macia Biotech) and used to transform DH5a strain of Escherichia coli
cells that had been made competent as described (29). The sequence of
the resulting GST/Pax-3 fusion cDNA was confirmed by DNA sequence
analysis (30) using a Sequenase version 2.0 kit (U. S. Biochemical Corp.).
GST/Pax-3 Production and Isolation—The GST/Pax-3 fusion protein
was prepared using the GST gene fusion system (Amersham Pharmacia
Biotech). Fusion protein production was induced with 0.1 mM isopropyl
b-D-thiogalactopyranoside (Sigma) for 2 h, and protein was isolated and
purified according to the manufacturer’s suggestions. Samples from the
initial bacterial cell lysate and the final bead eluates were analyzed by
SDS-polyacrylamide gel electrophoresis (31) using a 10% polyacryl-
amide gel. High molecular weight prestained protein standards (Life
Technologies, Inc.) were used to the estimate the sizes of the protein
products. Following electrophoresis, protein gels were either fixed and
stained with Coomassie Blue to visualize protein components (29) or
used for Western blotting as follows. Protein gels were electroblotted
with a Semi-Phor TE70 semi-dry blotter (Hoefer Scientific) onto Du-
ralon UV nylon membranes (Stratagene). Membranes and filter paper
were presoaked in transfer buffer containing 25 mM Tris, 200 mM
glycine, 20% methanol, and 0.01% SDS, then electroblotted for 1 h at
200 mA. Membranes were rinsed in TBS (10 mM Tris, pH 8.0, 150 mM
NaCl), then blocked for 1 h at room temp with rocking, in 1% dry milk
in TBS. Membranes were incubated with 10 ml of a 1:100 dilution of
mouse anti-GST antibody, kindly provided by Dr. Bill Kaelin (Dana
Farber Cancer Institute), diluted in 1% dry milk/TBS solution, and
rocked overnight at 4 °C. Following three subsequent 10 min washes
with TBS, membranes were incubated with 20 ml of a 1:5000 dilution
(100 milliunits) of goat anti-mouse IgG antibody solution (Oncogene
Science) and rocked for 1 h at room temperature. Three additional
10-min washes with TBS were followed by a 1-min rinse with 1 3 AP
buffer (100 mM Tris, pH 9.5, 100 mM NaCl, and 5 mM MgCl2). 30 ml of
AP buffer were mixed with 49.5 ml of 5-bromo-4-chloro-3-indolyl phos-
phate, then 99 ml of 4-nitroblue tetrazolium chloride (both from Boeh-
ringer Mannheim), after which the solution was immediately added to
the blot and rocked at room temp until color reaction appeared (approx-
imately 2–3 min). Reactions were stopped by rinsing the blot with
distilled H2O, and blots were subsequently stored in aluminum foil to
preserve color.
Assay for GST/Pax-3 DNA Binding Specificity—Ten nmol of double-
stranded e5 oligonucleotide were prepared by annealing equal molar
amounts of complementary oligonucleotides (GATCCTCGACTCTCAG-
CACCGCACGATTAGCACCGTTCCGCTCCCTGCA and GGGAGCG-
GAACGGTGCTAATCGTGCGGTGCTGAGAGTCGAG) (3) in 100 ml
containing 50 mM NaCl, 100 mM NaPO4. Reactions were heated to 85 °C
for 3 min, then the solution was allowed to cool slowly to room temper-
ature. Approximately 50 pmol were used for 39 end labeling reactions
(29) with 5 units of Klenow fragment of DNA polymerase, using 2 ml of
[32P]dGTP (3000 Ci/mmol). DNA was phenol-chloroform- and chloro-
form-extracted, ethanol-precipitated, and resuspended in 10 ml of H2O.
Approximately 20 fmol of probe were incubated with 1 ml of eluted GST
or GST/Pax-3 protein and 1 mg of poly(dI-dC) (Boehringer Mannheim),
in 90 mM KCl, 0.4 mM dithiothreitol, 2 mg/ml bovine serum albumin,
and 6.5% glycerol (32). Binding reactions were performed in the pres-
ence of unlabeled competitor DNA (e5, or E2, described below) at a 0-,
50-, 100-, or 200-fold molar excess and were carried out for 20 min at
30 °C and were electrophoresed for 2 h at 150 volts on a 0.75-mm 4%
nondenaturing polyacrylamide gel in 0.25 3 TBE. Gels were dried onto
3MM filter paper (Whatman) and exposed to film at 280 °C for 16–72 h.
Random Oligonucleotide Selection by Electrophoretic Mobility Shift
Assay—The sequence of the random oligonucleotide was designed ac-
cording to previously described flanking anchor sequences (33), for
cloning. This sequence, CGGGCTGAGATCAGTCTAGATCT(N)35GGA-
TCCGAGACTGAGCGTCGTC, where the XbaI and BamHI restriction
sites are underlined, and the internal BglII restriction site is indicated
in italics. An oligonucleotide containing the e5 sequence, and the fla-
nking anchor sequences in the random oligonucleotide, was designed to
be used as a control. The sequence of this oligonucleotide was: CGGG-
CTGAGATCAGTCTAGATCTGATCCTCGACTCTCAGCACCGCACGA-
TTAGCACCGTTCCGCTCCCTGCAGGATCCGAGACTGAGCGTCG-
TC, with internally designed restriction endonuclease digestion sites
indicated as above. Double-stranded radiolabeled probes were syn-
thesized by annealing each oligonucleotide with the following 39 anchor
primer: GACGACGCTCAGTCTCGGATCC, followed by extension with
Klenow, as described above, in the presence of 1 ml of [32P]dCTP in place
of unlabeled dCTP. Probes were electrophoresed on an 8% nondenatur-
ing acrylamide gel, and bands were excised and eluted overnight at
37 °C in 400 ml of acrylamide extraction buffer (0.5 M ammonium
acetate, 1 mM EDTA, 0.1% SDS, and 10 mM Tris-HCl, pH 7.5) (34). DNA
was phenol-chloroform- and chloroform extracted and precipitated with
0.25 M NaCl, 10 mg glycogen, and 3 3 volume of 100% ethanol for 1 h at
280 °C. DNA was resuspended in 100 ml of TE (10 mM Tris-HCl, pH 8.0,
1 mM EDTA), and incorporated radioactivity was measured in counts/
min (cpm) in a scintillation counter.
Binding site selection procedure was performed as described previ-
ously (35), with the following modifications. Between 12,000 and 15,000
cpm of probe were incubated with 1 ml of eluted GST/Pax-3 protein in a
20 ml of binding reaction containing 1 mg of poly(dI-dC), and 10 ml of
GST fusion protein binding buffer (36) (50 mM HEPES, pH 7.5, 50 mM
KCl, 5 mM MgCl2, 10 mM ZnSO4, mm dithiothreitol, and 50% glycerol),
for 30 min, at 30 °C. Reactions were electrophoresed as described above.
The initial binding reaction was electrophoresed on a nondenaturing
polyacrylamide gel alongside a complex of GST/Pax-3 and radiolabeled
e5 probe that was used as a migration control. The lane containing
random oligonucleotide was excised from the gel at the same position as
a GST/Pax-3ze5 complex, and bound DNA at that position was eluted
from the gel, phenol-extracted, and precipitated as described above.
Half of the eluted oligonucleotides were PCR-amplified in 50 ml of PCR
reactions containing 0.2 mM each of a 59 anchor primer, CGGGCT-
GAGATCAGTCTAGATCT, and the 39 anchor primer used for second
strand synthesis, 200 mM of each dATP, dTTP, and dGTP, 2 mM dCTP,
1 ml of [32P]dCTP (3000 Ci/mmol), 2.5 mM MgCl2, 1 3 AmpliTaq buffer
(Perkin-Elmer), and 5 units of AmpliTaq polymerase. 30 cycles of PCR
were performed using the following cycling conditions: 94 °C, 30 s;
55 °C, 2 min; 72 °C, 30 s; followed by a 5-min extension at 72 °C. PCR
reactions were electrophoresed on 8% nondenaturing polyacrylamide
gels and exposed to x-ray film for 1–3 min. Probes were excised, eluted,
precipitated, and counted, as described above. Approximately 12,000–
15,000 cpm were used for a subsequent round of binding and amplifi-
cation. This selection procedure was repeated for a total of four com-
plete rounds of enrichment, and following the fourth round of selection,
the final PCR products were digested with XbaI and BamHI, purified on
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an 8% polyacrylamide gel, and cloned into the XbaI-BamHI sites of the
pBluescript SK1 vector (Stratagene). The selected oligonucleotides are
referred to as SAAB (selected and amplified binding sites) (35) se-
quences. Individual clones were selected and digested with BglII to
verify the presence of insert. Sequencing of selected clones was per-
formed by the dideoxy chain termination method (30) with the Seque-
nase version 2.0 kit (U. S. Biochemical Corp.), using the supplied M13
240 reverse primer.
Competition Gel Mobility Shifts—Individual probes for gel shift as-
says were radiolabeled by PCR amplification using [32P]dCTP, as de-
scribed above for random oligonucleotide selection. DNA templates for
PCR included approximately 10–100 pmol of double-stranded oligonu-
cleotide (for the GST/Pax-3-selected random oligonucleotide pool, e5,
e5seq, and e5spac) or 100 ng plasmid DNA from cloned saab oligonu-
cleotides (for saab-1, saab-8, and saab-13). Probes were gel purified, as
described above, and resuspended in 100 ml of TE. Specific activity was
determined by counting 1 ml of resuspended probe in a scintillation
counter and calculating molar amount of probe from percent incorpo-
ration of labeled dCTP. Five to ten fmol of 32P-labeled probe were
incubated with GST/Pax-3 protein as described above, in the presence
or absence of unlabeled competitor oligonucleotide, as indicated in
figure legends. Sequences for oligonucleotides used for probes in com-
petition assays included e5, CGGGCTGAGATCAGTCTAGATCTATT-
AGCACCGTTCCGGATCCGAGACTGAGCGTCGTC; e5seq, CGGGCT-
GAGATCAGTCTAGATCTATTAGCACCGTTATGGATCCGAGACTGA-
GCGTCGTC; and e5 spac, CGGGCTGAGATCAGTCTAGATCTATTAA-
GTTCCGGATCCGAGACTGAGCGTCGTC. In addition, oligonucleo-
tides were designed to the saab-8 sequence, base-substituted for either
the ATTA or GTTAT motif. These two single site oligonucleotides were
designated PDbs (containing the putative paired domain binding site):
GACGACGCTCAGTCTCGGATCCTAATAATGAACATGTATGCCGTA-
TATTTAGTTATTAGATCTAGACTGATCTCAGCCCG and HDbs (con-
taining the putative homeodomain binding site): CGGGCTGAGATCA-
GTCTAGATCTACGCCGTAAATATATAATATACATGTTCATTATTA-
GGATCCGAGACTGAGCGTCGTC. Retained putative binding sites are
shown in boldface, and mutated bases are underlined. Sequences of the
homologous competitors for each selected oligonucleotide were AGCT-
TTAGTGAATTATGTTATTAAAATGGTCTAGAC (for saab-1), AGCTT-
TGTATATTATATATTTAGTTATGGTCTAGAC (for saab-8), and AGC-
TTATTATGTTTTACTAGATGTTATGGTCTAGAC (for saab-13). Reac-
tions were analyzed on a 4% nondenaturing polyacrylamide gel, which
was subsequently dried onto Whatman 3MM paper, and exposed to
x-ray film at 280 °C, overnight.
Electrophoretic Mobility Shift Assay Quantitation—Dried gels from
gel mobility shift assays were exposed on a phosphor screen for 16–72
h, and images were scanned on a PhosphorImager (Molecular Dynam-
ics). Bands were analyzed and quantitated with ImageQuant software
(Molecular Dynamics).
Construction of Reporter and Expression Plasmids—The Rf1-Pax-3
expression plasmid (28), obtained from George Chalepakis (here re-
ferred to as pCMV/Pax-3), was used for co-transfection experiments. A
negative control expression plasmid, referred to as pCMV, was derived
from pCMV/Pax-3 by excision of the Pax-3 cDNA fragment with BamHI
and XbaI. Blunt ends were formed using the Klenow fragment of DNA
polymerase (New England Biolabs), electrophoresed on a 1.2% agarose
gel, and linearized plasmid was excised from the gel and purified by
Geneclean methods. The plasmid was circularized with T4 DNA Ligase.
For construction of reporter plasmids, double-stranded saab-1,
saab-8, and saab-13 oligonucleotides (described above), as well as a
PRS-9 control (AGCTTGATTAGCACCGTTACGGTCTAGAGGTCTA-
GC) were kinased with T4 polynucleotide kinase (New England Bio-
labs). The pTKGH reporter plasmid (HGH-TGES 100T kit, Nichols
Institute), which contains herpes simplex virus thymidine kinase pro-
moter sequences fused to the hGH (human growth hormone) gene, was
digested with HindIII and dephosphorylated as described above. 50 ng
of each double-stranded oligonucleotide was used in ligation reactions
along with 100 ng of HindIII-digested dephosphorylated pTKGH. Indi-
vidual clones were used in PCR reactions containing primers designed
to the pTKGH plasmid, flanking the site of insertion, to verify the
presence of insert. These forward and reverse primers were GTAAAAC-
GACGGCCAGTG and TGAAGCAGGACCTGCAGC, respectively. The
sequences of inserts were verified by sequencing with an upstream
primer designed to the pTKGH vector, GCAAGGCGATTAAGTTGG.
Recombinant reporter plasmids contained PRS-9, saab-1, and saab-13
inserts with the ATTA 59 to the GTTAT element, and the saab-8 insert
was found in the opposite orientation.
Transfections—NIH-3T3 cells were maintained in Dulbecco’s modi-
fied Eagle’s medium supplemented with 10% fetal calf serum, 10 mM
HEPES, pH 7.4, 50 units/ml penicillin (Life Technologies, Inc.), 50
mg/ml Streptomycin (Life Technologies, Inc.), and 2 mM L-glutamine
(Life Technologies, Inc.) and were grown in 5% CO2 at 37 °C. Cells were
plated in 35-mm tissue culture plates and transiently transfected when
they were 60–70% confluent with a total of 30 mg of DNA by CaPO4-
mediated transfection, using the CellPhect transfection kit (Amersham
Pharmacia Biotech). 10 mg of reporter plasmid, 10 mg of pCMV/Pax-3 or
pCMV, and 10 mg of calf thymus DNA (Sigma) were used to transfect
duplicate cultures, in three separate experiments. DNA precipitates
were incubated with cells for 16 h, followed by removal of the precipitate
and incubation for 1 h with fresh medium. This medium was again
replaced, and cells were incubated for an additional 48 h. At the end of
the culture period, media were collected for secreted growth hormone
assays, using the HGH-TGES 100T radioimmunoassay kit (Nichols
Institute), according to the manufacturer’s suggested protocol. hGH
standards, provided with the kit, were diluted with medium to deter-
mine a standard curve for each individual assay, to estimate actual
amounts of hGH expression. Results of four repeated transfection ex-
periments performed on successive days, each of which was performed in
duplicate plates for each combination of transfected DNA, was analyzed
statistically by analysis of variance, followed by post hoc Duncan’s multi-
ple range test, using a Statistica software application for the Macintosh.
RESULTS
Selection of Pax-3 Binding Sequences among Random Oligo-
nucleotides Using Both DNA-binding Domains of Pax-3—To
express both of the Pax-3 DNA-binding domains for selection of
novel binding sequences, a GST/Pax-3 fusion vector was con-
structed as described under “Experimental Procedures.” This
GST/Pax-3 fusion protein was able to bind to an oligonucleotide
containing the Drosophila e5 sequence, a cognate Pax-3 bind-
ing element, as shown by gel mobility shift assay (Fig. 1). A
single shifted complex was formed in the presence of the GST/
Pax-3 fusion protein (Fig. 1, lane 1), and this complex was
competed by 50–200-fold molar excess of unlabeled e5 oligonu-
cleotide (Fig. 1, lanes 2–4). In contrast, a nonspecific oligonu-
cleotide, derived from nt 230 to 140 of the adenovirus E2A
promoter (E2), did not compete for binding (Fig. 1, lanes 5–7),
demonstrating that the interaction between GST/Pax-3 and e5
was specific. The GST protein alone failed to form a complex
with the e5 probe (Fig. 1, lane 8), demonstrating that the DNA-
binding domains of Pax-3 were required for this interaction.
This GST/Pax-3 fusion protein was used in the selection of
Pax-3 binding sites from a pool of random oligonucleotides
using a modification of the “saab” (selected and amplified bind-
ing sites) procedure (35). The separation of GST/Pax-3-bound
radiolabeled oligonucleotides from unbound oligonucleotides
was accomplished by nondenaturing gel electrophoresis. A total
of four rounds of selection and amplification were performed. No
radiolabeled DNA was detected at the position that co-migrated
with an e5 probe bound to GST/Pax-3 following the first round of
FIG. 1. Gel mobility shift assay of binding reactions performed
with GST/Pax-3 fusion protein or GST control protein, and ra-
diolabeled e5 probe. Reactions were performed in the absence or
presence of 0 (lanes 1 and 5), 50- (lanes 2 and 6), 100- (lanes 3 and 7),
or 200- (lanes 4 and 8) fold molar excess of unlabeled specific (e5), or
nonspecific (E2), competitor. The specific shifted complex in indicated.
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selection (Fig. 2, lane 1), however, by the second round, a shifted
complex was detected (Fig. 2, lane 2). The enriched pool of oligo-
nucleotides that was obtained after the fourth round of selection
was specifically competed with excess e5 competitor (Fig. 2, lanes
6 and 7), but not with the nonspecific E2 competitor (Fig. 2, lanes
8 and 9), demonstrating that GST/Pax-3 binds specifically to the
pool of randomly selected oligonucleotides.
Sequence Analysis of GST/Pax-3 Selected Oligonucleotides—
The enriched pool of GST/Pax-3 binding sequences was cloned
into plasmid and sequenced. Of 47 independent clones that
were sequenced, 45 were unique. All but two of these sequences
contained at least one ATTA motif, the core homeodomain
recognition sequence. In addition, all but one of the selected
oligonucleotides contained a “GTNNN” motif, but none con-
tained either the paired domain recognition sequence of e5
(GTTCC) or a base-substituted derivative of the paired domain
binding site of e5, PRS-9 (GTTAC), to which Pax-3 can also
bind (20). Instead, the sequence, GTTAT, which has not previ-
ously been identified in any Pax-3-binding elements, was pres-
ent in 14 (33%) of the selected clones. Nine of the GTTAT-
containing oligonucleotides, representing 20% of the 45 unique
sequences, also contained an upstream ATTA. No other novel
consensus element distinct from GTNNN was found among the
selected oligonucleotides. Interestingly, the sequences between
the ATTA and GTTAT were variable both in length (consisting
of 1, 4, 5, 8, or 13 bases) and in base composition; the only
apparent similarity of sequence on either side of the ATTA and
GTTAT was an “A” or a “T.” The selected oligonucleotides
containing this consensus are shown in Fig. 3.
Binding Characteristics of Selected Sequences—Three of the
nine sequences containing the consensus binding site were fur-
ther evaluated. Specific probes were made for saab-1, saab-8, and
saab-13, which contained 1, 8, or 13 bp between the ATTA and
GTTAT elements, respectively (Fig. 3). Specificity of binding to
GST/Pax-3 by each probe was tested in gel mobility shift assays,
using homologous competitor oligonucleotides (Fig. 4). With each
probe, a single complex was observed in the absence of competitor
DNA, and this complex was competed by both the homologous
(lanes 2, 7, and 12) and e5 oligonucleotides (lanes 3, 8, and 13),
but not with the nonspecific E2 oligonucleotide (lanes 4, 9, and
14). These observations suggest that the interactions between
each of the selected probes and GST/Pax-3 were specific.
Previous studies have indicated that oligonucleotides in
which a paired domain and a homeodomain binding element
were either very closely spaced or widely separated bind poorly
or not at all (22). In addition, binding of many proteins to DNA
is sensitive to the phasing around the DNA helix on which
recognition elements are located (37, 38). Although Fig. 4
showed that each of the oligonucleotides with variable spacing
could be bound by Pax-3, it was possible that each was bound
with different affinities. To test this, binding competition anal-
yses were performed with increasing amounts of homologous
competitor for each of the e5, saab-1, saab-8, and saab-13
probes, and the concentration of competitor that inhibited bind-
ing by 50% was used to determine relative binding affinity (Fig.
5A). By this method, the affinity of GST/Pax-3 for e5 and saab-8
was equal, but it was reduced by 9- and 12-fold, respectively,
for saab-1 and saab-13 (Fig. 5B). These results indicate that the
tested oligonucleotides fall into at least two distinct categories
of Pax-3 binding affinity: a higher affinity group, containing the
e5 sequence and the saab-8 selected sequence, and a lower
affinity group, containing the saab-1 and saab-13 sequences.
Effect of Sequence and Spacing of the DNA Consensus Se-
quence on Pax-3 Binding Affinity—The existence of at least two
affinity classes of specific Pax-3 binding sites among the tested
oligonucleotides prompted us to examine whether the variable
length of the intervening spacer region was an important de-
terminant for high affinity binding. To test this, four of the five
nt between the core binding elements of the e5 oligonucleotide
FIG. 2. Random oligonucleotide binding site selection with
GST/Pax-3. A radiolabeled pool of oligonucleotides was incubated with
the eluted GST/Pax-3 protein and reactions separated by nondenatur-
ing gel electrophoresis as described under “Experimental Procedures.”
The shifted complex from each lane was excised, reamplified, and used
in the subsequent binding reaction. After four rounds of selection, the
enriched pool of oligonucleotides was tested for binding specificity by
competition gel shift assays using 0 (lane 5), 50 (lanes 6 and 8), and 100
(lanes 7 and 9) ng of specific (e5) or nonspecific (E2) unlabeled competitor.
FIG. 3. Alignment of sequences containing the “ATTA-Nn-GT-
TAT” consensus sequence for GST/Pax-3, where “n” represents a
variable intervening spacer length between the two putative
binding sites. The ATTA and GTTAT of the derived consensus se-
quences are indicated in bold. The presence of an indentical spacer
sequence in the two n 5 13 clones could indicate that a single sequence
was selected and that during subsequent PCR, a single base change (see
“T” at position 2 of the top sequence and “A” at position 1 of the bottom
sequence) occurred, resulting in two different clones containing an
almost identical sequence.
FIG. 4. Binding specificity of subset of selected oligonucleo-
tides. Gel mobility shift assay of binding reactions contained radiola-
beled probe made from each of three GST/Pax-3 selected oligonucleo-
tides (saab-1, saab-8, and saab-13) and GST/Pax-3, in the presence of 0
(lanes 1, 6, and 11) or 250-fold molar excess of either unlabeled homol-
ogous competitor (self, lanes 2, 7, and 12), e5 (lanes 3, 8, and 13), or
nonspecific E2 (lanes 4, 9, and 14) oligonucleotide.
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were deleted, leaving a single “T,” as found in the lower affinity
saab-1 oligonucleotide. This mutation (e5spac) significantly re-
duced both the total binding capacity and binding affinity of e5
(Fig. 5C, lanes 6–10). Thus, the lower GST/Pax-3 binding af-
finity observed for saab-1 is likely because of constrained bind-
ing imposed when the two recognition sequences are placed
only 1 bp apart from each other. Constrained binding when
elements are too far apart may also be the explanation for the
lower binding affinity for saab-13. The variation of the se-
quence of the presumed paired domain binding site, in con-
trast, did not appear to be responsible for the reduced affinity
of the saab-1 or saab-13 oligonucleotides, because substitution
of the “GTTCC” core paired domain binding sequence of e5 for
GTTAT (mutation e5seq) had no apparent effect on binding
affinity (Fig. 5C, lanes 11–15). This latter result was to be
expected, because the presence of the GTTAT instead of GT-
TCC in the saab-8 oligonucleotide did not impair binding (Fig.
5A). Indeed, the similar affinities of GST/Pax-3 for e5 and
saab-8, in which the core recognition elements are separated by
5 and 8 bp, respectively, suggests that spacing variation, even
when the orientations of the putative contact sites for the
paired and homeodomains are oriented differently by one-third
of a turn around the DNA helix, is remarkably flexible.
Single-site Oligonucleotides Can Compete for Binding to
Pax-3, but with Lower Affinity—To test whether both the ATTA
and GTTAT were necessary for binding to GST/Pax-3, oligonu-
cleotides were synthesized to contain base substitutions replac-
ing either the ATTA or the GTTAT element of the high affinity
saab-8 oligonucleotide, and these oligonucleotides were tested
for their abilities to compete for binding to e5 or to each of the
three saab probes. As shown in Fig. 5D, oligonucleotides in
which either of these elements was mutated competed signifi-
cantly for binding to each of the probes, but neither of the single
site oligonucleotides competed as efficiently as excess e5 compet-
itor that contains both Pax-3 binding elements. Thus, whereas
both sites are necessary for optimal binding, either one or the
other of the putative binding sites found in our saab oligonu-
cleotides can be deleted without eliminating Pax-3 binding.
Regulation of Selected Binding Sites by Pax-3 during Tran-
sient Transfection—Previous studies have shown that Pax-3
FIG. 5. Relative affinities of selected oligonucleotides for GST/Pax-3. A, gel mobility shift following binding reactions containing
radiolabeled probes for e5, saab-8, saab-1, and saab-13, with GST/Pax-3 and either zero (lanes 1, 6, 11, and 16) or increasing amounts of unlabeled
homologous competitor. 150-, 300-, 600-, and 900-fold molar excess of homologous competitor were used for the e5 and saab-8 oligonucleotides,
whereas 750-, 1500-, 3000-, and 6000-fold molar excess of homologous competitor was used for the saab-1 and saab-13 oligonucleotides. B,
inhibition of Pax-3 binding by homologous competitor oligonucleotides. Quantitation of probe binding in the presence of increasing amounts of
competitor from four representative binding reactions as shown in A, plotted as a percent of total binding in the absence of competitor. C,
competition gel shift assay using 10 fmol of radiolabeled probes for the e5 (lanes 1–5), e5spac derivative (lanes 6–10), or the e5seq derivative (lanes
11–15), and GST/Pax-3, in the presence of zero (2) or 10-, 50-, and 100-fold molar excess of homologous competitor. F, free probe. D, competition
gel shift assay using 10 fmol of radiolabeled probe for e5 (lanes 1–6), saab-8 (lanes 7–12), saab-1 (lanes 13–18), and saab-13 (lanes 19–24), with
GST/Pax-3 and either 0 (2) or 200-fold molar excess of unlabeled competitor containing the e5 binding site (e5), the saab-8 oligonucleotide base
substituted at the putative homeodomain binding site (PDbs), the saab-8 oligonucleotide base substituted at the putative paired domain binding
site (HDbs), or the nonspecific E2 oligonucleotide. F, free probe.
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will trans-activate reporter plasmids containing the e5 se-
quence (ATTA-N5-GTTCC) or a base-substituted derivative of
e5 (ATTA-N5-GTTAC), called PRS-9 (24, 39, 40). To determine
whether the in vitro selected saab Pax-3 binding sequences
could be regulated by Pax-3 in living cells, each sequence was
inserted into a pTKGH reporter plasmid, which contains the
basal promoter element of the herpes virus thymidine kinase
promoter linked to the human growth hormone reporter gene.
A pTKGH plasmid containing the PRS-9 sequence was used as
a positive control for Pax-3 trans-activation. PRS-9, rather
than e5, was chosen as a control, because its paired domain
binding sequence (GTTAC) more closely resembles the saab-
selected GTTAT sequence than does the paired domain binding
sequence of e5, and it has also been shown to be Pax-3-respon-
sive in transfection assays (24). Reporter plasmids containing a
single copy of either the PRS-9, saab-1, saab-8, or saab-13
sequence were generated and co-transfected into NIH-3T3 cells
along with either a Pax-3 expression plasmid directed by the
CMV promoter/enhancer sequences (pCMV/Pax-3) (28) or a
control plasmid containing the CMV promoter/enhancer but
lacking any Pax-3 cDNA sequence (pCMV). As shown in Fig. 6,
expression of hGH from plasmids containing each of the tested
inserts was increased upon co-transfection with pCMV/Pax-3,
although to differing degrees. Only trans-activation of the plas-
mids containing the high affinity binding elements was statis-
tically significant. In fact, the greatest trans-activation was
observed using the saab-8-containing plasmid (13-fold), fol-
lowed by PRS-9 (5.5-fold). Lower levels of activation were ob-
served using the saab-13 sequence (3.9-fold) and the saab-1
sequence (1.7-fold), and these levels of activation were not
significantly different from that of pTKGH. These results dem-
onstrate that sequences that bind with higher affinity to Pax-3
mediate greater trans-activation by Pax-3 in living cells.
DISCUSSION
The purpose of this study was to search for optimal binding
sequence(s) for Pax-3 using its combined paired domain and
homeodomain. Identification of this sequence could then assist
in the recognition of Pax-3 response elements in Pax-3-regu-
lated genes. In the course of this work, we identified a consen-
sus sequence that contains a previously unidentified paired
domain recognition motif (GTTAT) located within 13 bp down-
stream of the known homeodomain recognition motif (ATTA).
As well, we evaluated the effect of spacing of the ATTA and
GTTAT on binding affinity and transcription regulation. The
identification of GTTAT as a new paired domain recognition
motif is noteworthy, because it is found in regulatory elements
of at least two Pax-3-responsive genes, and trans-activation
analysis demonstrated that it is even more responsive to Pax-3
than the previously studied PRS-9 element. When our results
are taken in conjunction with the findings of others, in which
Pax-3 can bind to an e5 variant containing the sequence, GT-
TAC (20), and the paired domain alone can bind to a GTCAC
motif (23, 32), this suggests that the consensus element for the
paired domain of Pax-3 can now be considered to be, GTPyA/
CPy. The absence of any other completely novel paired domain
consensus element among our saab-selected oligonucleotides
would indicate that some variation of the GTPyA/CPy sequence
is essential for binding by the Pax-3 paired domain.
Effect of Spacing between Homeodomain and Paired Domain
Recognition Elements—GST/Pax-3 bound with similar affini-
ties to the e5 element, in which the homeodomain and paired
domain recognition sequences are separated by 5 nt, and to our
saab-8 element, in which these elements are separated by 8 nt.
The absence of an effect of different positions of the paired and
homeodomain recognition elements around the DNA helix on
binding affinity is quite unusual. Other regulatory proteins, for
example, adenovirus E2F and l repressors, must be localized at
particular positions along the turns of the double helix in order
for binding and regulation to occur (37, 38). One interpretation
of these observations is that multimeric factors such as E2F
and l repressors assemble as complexes on DNA which are
relatively inflexible, but a bipartite factor such as Pax-3, which
binds as a monomer, can bend as both DNA-binding domains
grasp their contact sites on the DNA. To our knowledge, this is
an unprecedented characteristic of DNA-binding factors. When
spacing requirements of POU proteins, another class of bipar-
tite DNA-binding factors, which contain a POU domain and a
POU-type homeodomain, has been examined, such flexibility
has not been observed. For example, Brn-3, a member of the
POU-IV class of transcription factors, will only bind to DNA
when core motifs are separated by 3 nt (41). Brn-2, a member
of the POU-III class of transcription factors, will tolerate spac-
ing of the core motifs by either 0, 2, or 3 nt, but exhibits
variable affinities for elements with differential spacing (41).
On the other hand, the ability of the Pax-3 DNA-binding
domains to grasp its recognition elements at different locations
does not appear to be unlimited, as reducing the distance
between ATTA and GTTAT to 1 nt, or increasing it to 13 nt,
markedly reduced binding affinity. Indeed, if the binding se-
quences are too close or too far apart from each other, simul-
taneous occupancy of DNA by both binding domains appears to
be constrained, resulting in low affinity binding that was in-
distinguishable from binding to a single site and poor tran-
scriptional responsiveness. Whereas others similarly found
that when the paired domain and homeodomain recognition
elements were separated by as few as 2 bp or as many as 15 bp,
little or no binding occurred (22), our results indicate that weak
binding can occur under such circumstances and might be
associated with a modest transcriptional response.
Relationship of High and Low Affinity Binding to Regulation
of Genes during Development—Although others have not de-
tected binding of Pax-3 to either the homeodomain recognition
sequence (20) or to the paired domain recognition sequence (30)
in the absence of the other, our results, in which oligonucleo-
tides containing only one or the other putative Pax-3 recogni-
tion sequence competed for binding to e5, demonstrated that
the GST/Pax-3 fusion protein will recognize each individual
binding element in the absence of the other. However, these
interactions with only one recognition element appear to be of
FIG. 6. Activation of hGH expression by reporter plasmids
containing Pax-3 binding sequences. Four replicate transient
transfection experiments of NIH-3T3 cells with indicated reporter con-
structs were co-transfected with either pCMV or pCMV/Pax-3 expres-
sion plasmids. -Fold activation of each reporter plasmid was deter-
mined from the ratio of hGH expressed by cultures co-transfected with
pCMV-Pax-3 to those co-transfected with pCMV. *, p , 0.02, and #, p ,
0.05, compared with plasmid with no Pax-3 binding elements.
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low affinity, similar to those in which the recognition elements
are either too close or too far apart.
Whether the presence of a single binding element is suffi-
cient to activate transcription was not tested here. However,
because neither of the low affinity saab-1 nor saab-13 elements
were significantly trans-activated, it would be expected that
genes associated with single elements would be weakly trans-
activated as well. If this is the case, then it should be noted that
almost all of the potential Pax-3 binding sequences found in the
few identified Pax-3-responsive genes are low affinity. In the
myelin basic protein promoter, there is one inverted GTTAT
and two inverted GTTCC elements, but none of these elements
is located in the proximity of a homeodomain binding element
(42). Similarly, the human c-MET promoter contains one in-
verted GTTCC, and a similar element, GGTCC, but no nearby
homeodomain binding element (43). The chicken myoD pro-
moter, on the other hand, contains two inverted GTTAT ele-
ments located 15 and 18 nt upstream of inverted ATTA ele-
ments, three GTTCC elements located 1, 9, 12, or 15 nt
downstream of ATTA elements, and four additional GTTAT or
GTTCC elements located at least 200 bp away from homeodo-
main recognition elements. Because, based on the results pre-
sented here, only the GTTCC located within 9 nt of the ATTA
of the myoD promoter is likely to bind Pax-3 with high affinity,
it might be the only element that is significantly responsive to
Pax-3 at the transcriptional level. Further identification of
Pax-3-responsive genes and examination of effects of mutation
of putative Pax-3 binding elements on transcriptional responsive-
ness will be necessary before the biological significance of these
sequences in naturally occurring genes can be appreciated.
Although activation of the saab-13 element was not signifi-
cantly greater than that of the basal TK promoter, it was also
not significantly less than that of the PRS-9 element. Perhaps
modest activation of genes associated with low affinity Pax-3
binding sites occurs when nuclear Pax-3 levels are very high.
Likewise, because high affinity Pax-3 binding sites require a
lower concentration of Pax-3 for stable binding, genes that
possess these elements would be preferentially expressed when
there are low levels of Pax-3 have accumulated in the cell.
These may be the genes that are turned on first during the
induction of Pax-3 expression in a given embryonic tissue. This
model is similar to that suggested for heat shock factor activa-
tion of heat shock response genes, whereby the preferential in-
duction of the hsp 82 gene, over other heat shock response genes,
appeared to be because of the higher affinity of heat shock factor
for the binding site located upstream of the hsp 82 gene (44).
Alternatively, it is intriguing to speculate that winding of DNA
along histones could convert some low affinity elements into high
affinity elements by arranging distant paired domain and home-
odomain binding sites into close proximity to one another.
The sensitivity of genes associated with high and low affinity
Pax-3 binding sites to relative nuclear levels of Pax-3 may help
to explain how Pax-3 mutations lead to congenital malforma-
tions in mice and humans. For example, Pax-3 mutations in
heterozygous Splotch mice cause only pigmentation defects,
with apparently normal neural tube development. Thus, one
might predict that the lower level of Pax-3 expression in het-
erozygotes is enough to activate high affinity response genes
controlling neural tube development, but that the threshold of
Pax-3 expression required for activation of lower affinity re-
sponse genes in melanocyte precursors derived from the neural
crest is not met. Similarly, maternal diabetes, which causes
expression of Pax-3 to be significantly reduced and is associ-
ated with increased neural tube defects (8), may lower the level
of Pax-3 below a threshold required to activate the normal
complement of Pax-3-responsive genes, with low affinity tar-
gets being particularly affected. Identification of additional
Pax-3-responsive genes and their associated transcription con-
trol elements will be needed to more completely understand the
functional significance of high and low affinity Pax-3 binding
sites during embryonic development.
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